IGC Pharma, Inc. (IGC) Research

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

Market snapshot

Symbol
IGC
Price
$0.27
Day change
-0.29%
Market cap
$27.5M
P/E ratio
-3.99x
52-week range
0.24-0.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 7 days

Peer companies

  • AN2 Therapeutics, Inc. (ANTX)
  • Boundless Bio, Inc. (BOLD)
  • Intensity Therapeutics, Inc. (INTS)
  • Iterum Therapeutics plc (ITRM)
  • Nutriband Inc. (NTRB)
  • NextCure, Inc. (NXTC)
  • Pluri Inc. (PLUR)
  • Plus Therapeutics, Inc. (PSTV)

Recent insider activity

  • PRINS RICHARD K — M-Exempt (70000 shares) on 2026-04-01
  • PRINS RICHARD K — M-Exempt (100000 shares) on 2026-04-01
  • PRINS RICHARD K — M-Exempt (70000 shares) on 2026-04-01
  • PRINS RICHARD K — M-Exempt (100000 shares) on 2026-04-01
  • Mukunda Ram — M-Exempt (323077 shares) on 2026-04-01

Open IGC Pharma, Inc. (IGC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.